

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6



FIG. 7




FIG. 8




FIG. 9



A
Control antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)
B
NI-101.11 antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)
C
22C4 antibody + Abeta42-FITC monomer
215 nm (antibody)
280 nm (antibody)
495 nm (Abeta-FITC)

FIG. 10A-C




FIG. 11




FIG. 12




FIG. 13




FIG. 14A-B




FIG. 15




FIG. 16A-B




FIG. 17




FIG. 18A-E




FIG. 19A-B



Microhemorrhages
cortex and hippocampus
6
5
4
3
2
1
0
wt
tg
control
NI-101.11

FIG. 20



fluorescence (arb. units)
40
30
20
10
0
Monomer
Fibrils
10 nM NI-101.11
100 nM NI-101.11
1 uM NI-101.11

FIG. 21



50
40
30
20
10
0
% FITC positive cells
0
20
40
60
80
100
antibody concentration [ug/ml]
NI-101.11
6E10
control

FIG. 22